Who We Are
We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs.
“Our team at Arena is driven to deliver new, best-in-class treatments that address unmet medical needs and improve the health of patients. We look forward to BELVIQ’s upcoming US launch and will continue innovating to advance additional novel drug candidates through our validated platform.”
-Jack Lief, President and Chief Executive Officer
BELVIQ is approved by the US Food and Drug Administration and will be available in the US only after its Schedule IV designation is effective on June 7, 2013.